Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robots take aim at lung nodules: could precision ablation replace surgery?

NCT ID NCT07389889

Disease control Sponsor: Fujian Medical University Union Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This trial tests whether a robot can help doctors more accurately target and destroy small lung nodules (ground-glass opacities) using microwave heat, compared to the standard CT-guided method. About 116 adults with early-stage lung cancer who cannot have surgery will be randomly assigned to one of the two techniques. The main goal is to see if the robot improves first-attempt puncture success and reduces complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
microwave ablation
What this could lead to
If successful, robot-guided ablation could become a more precise and safer option for treating early-stage lung nodules without surgery.
What could go wrong
This is an early-stage trial with only 116 participants, so results may not apply broadly. The robot may not improve outcomes enough to justify its cost or complexity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 to 85 years 2. Nodules measuring 3-30mm with ground-glass opacities constituting ≥75% of the lesion 3. Preoperative clinical evaluation confirming no hilar or mediastinal lymph node metastasis and no distant metastasis 4. Patients diagnosed as stage IA primary peripheral lung cancer according to the UICC 8th TNM staging system, and with one of the following conditions: (i) cannot undergo surgical resection due to poor cardiopulmonary function or advanced age (ii) refusing or unwilling to undergo surgical resection (iii) with newly developed or residual pulmonary nodules after early-stage primary lung cancer surgery (iv) with unilateral lung disease who cannot undergo unilateral surgical resection (v)with multiple primary lung cancers unsuitable for surgical resection 5. Preoperative ECOG physical status score is 0/1 6. ASA score is I-III 7. Patients voluntarily participate in this study and sign the informed consent form Exclusion Criteria: 1. Smoking cessation duration \<2 weeks 2. Lesions adjacent to pulmonary artery-vein main trunks 3. Lesions near the hilum or adjacent to lobar bronchi 4. Pregnancy or lactation status 5. Severe mental disorders 6. History of other malignancies within 5 years 7. Unstable angina or myocardial infarction within 6 months with coronary angiography showing severe stenosis of major coronary branches 8. Cerebral infarction or hemorrhage within 6 months 9. Continuous systemic corticosteroid therapy within 1 month 10. Patients or their authorized persons who do not wish to comply with the study protocol 11. Patients with other investigator-assessed ineligibility for the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ground-glass opacity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Multiple Pulmonary Nodules

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ground-glass opacity Pulmonary nodules

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.